A review of the literature for the most interesting published applications utilizing iCell Cardiomyocytes in 2015
Understanding and defining the effects of compounds on cardiac function is critically important in drug discovery and toxicity testing. CDI’s iCell Cardiomyocytes and iCell Cardiomyocytes2 provide a relevant and validated system for studying pharmacological effects on human cardiomyocyte activity.
The world of iPSC-derived hepatocytes is no longer flat. CDI has identified protocols enabling the formation of stable 3D spheroids in culture.
CDI’s iCell® Skeletal Myoblasts provide an excellent model for investigating the etiology, pathology, and potential treatments of type 2 diabetes while Promega’s Ultra-Glo™ reagents offer easy-to-use, highly sensitive, and robust detection reagents for a variety of cellular processes.
High Throughput Screening Applications: Learn how to use iCell Cardiomyocytes2 in 1536-well screening assays.
Learn about recently released methodology for video analysis of cardiomyocyte function.
Foreseeing drug-induced arrhythmia is a critical component of drug development and the FDA is seeking to increase the predictivity of pre-clinical testing strategies via the Comprehensive In Vitro Proarrhythmia Assay (CIPA) initiative.
Myocardial ischemia is a pathological condition characterized by a reduced oxygen supply that can lead to cellular apoptosis/necrosis, arrhythmia, organ injury, and even death.
The primary goal of the CIPA initiative is to utilize mechanistic understanding of cardiac electrophysiology to create a more predictive biomarker for drug-induced Torsades de Pointes (TdP). The current biomarkers of hERG ion channel block and QT prolongation are highly sensitive endpoints with low selectivity and thus potentially result in unnecessary attrition.